8:00 am Virtual Coffee & Online Registration

8:45 am Chair’s Opening Remarks


9:00 am Modulation Of The Tumor Micro-Environment By Oncos-102 – Experience From Several Types Of Cancer


• ONCOS-102 acts synergistically to reduce tumor volume with the chemotherapy combination of pemetrexed and cisplatin (Pem/Cis), which is the current standard of care in malignant pleural mesothelioma
• Demonstration that ONCOS-102 induces CD8+ T-cells specific to the tumor associated antigen (TAA) mesothelin, which is typically overexpressed in mesothelioma, as well as many other forms of cancer

9:30 am Resurrecting and Supporting the Immune Response with Combination Therapy to Cure Pancreatic Ductal Adenocarcinoma


• Utilizing therapeutic interventions to create an internal vaccine.
• Rational utilization of PD-1 inhibitors in the treatment of PDAC.
• Complementing the immune response against cancer with EGFR/KRAS combination therapy

10:00 am Neoantigen Vaccination for Glioblastoma: Does Timing of Anti-PD-1 Matter?

  • David Reardon Clinical Director, Center for Neuro- Oncology, Dana-Faber Cancer Institute


• Better understand the rationale of combining neoantigen vaccination with anti-PD-1 therapy;
• Gain awareness of increasing preclinical data implicating how the timing of anti-PD-1 therapy may impact on anti-tumor immune responses generated by neoantigen vaccination;
• Appreciate the challenges of assessing the impact of anti-PD-1 timing on anti-tumor immune responses generated by neoantigen vaccination in a prospective clinical trial.

10:30 am Morning Break & Speed Networking

11:15 am Understanding Mechanisms Of Immune Resistance In Nsclc Through Analysis Of The T Cell Repertoire

  • Alexandre Reuben Assistant Professor, The University off Texas MD Anderson Cancer Center


• Substantial intratumor genomic and T cell heterogeneity (ITH) in earlystage NSCLC
• High frequency of bystander T cells are present in lung tumors
• Patients with more ITH and/or bystander T cells experience worse outcome
• Lung TILs recognize viral antigens
• Bystander TILs exhibit an unfavorable profile for anti-tumor responses
• Animal models allow the analysis of these phenomena and therapeutic strategies to overcome them
• Analysis of these mechanisms in patients treated with immunotherapy underway

11:45 am Altering the Human Prostate Tumor Immune Microenvironment Through Inhibition of Ibrutinib

  • Russell Pachynski Assistant professor, Division of Oncology, Washington University School of Medicine


• This is the first clinical trial of the BTK inhibitor ibrutinib in prostate cancer
• Ibrutinib may alter favorably alter the prostate tumor microenvironment by reducing pro-tumor B cells and increasing anti-tumor T cells
• Inhibition of BTK may also limit tumor cell-intrinsic growth
• Prostate tissue and peripheral correlative studies will be performed to evaluate the further use of ibrutinib in prostate cancer

12:15 pm Next Generation Cancer Vaccine-Adjuvant Combinations

  • Mark Findeis Executive Director, Research Biochemistry, Agenus Bio


• Heat shock protein as neoantigen peptide chaperone
• High-yield synthesis of neoantigen peptides
• New adjuvant manufacturing and formulations to combine with vaccines

12:45 pm Lunch Break & Virtual Networking


1:45 pm A Novel Heterologous Prime Boost Vaccine System To Drive Tumor Specific T Cell Responses For Cancer Immunotherapy

  • Karin Jooss Chief Scientific Officer, Gritstone Oncology


• Development of a potent heterologous prime/boost immunization approach to deliver predicted TSNAs to patients, which is comprised of a replication incompetent chimpanzee adenoviral vector (ChAdV) for the prime vaccination and a self-replicating, synthetic viral vector (srRNA) for repeated boost vaccinations
• Induction of high titer, polyfunctional and durable T-cell responses against non-self antigens
• Clinical trial updates will be highlighted

2:15 pm Optimizing the Efficacy of mRNA-based Cancer Vaccines to Generate Potent and Long-lasting CD8+ Responses


• Learning from preclinical models to guide and optimize mRNA-based vaccine platforms
• Deciding the best combination therapy to use with mRNA
• Determining anti-tumor T cell efficacy and future directions

2:45 pm Targeting Unique Neoantigens From Individual Patient Tumors To Develop Novel Treatment For Cancer


• Optimized DNA plasmid containing encoded neoantigens, used in combination with IL-2 to boost T cell response
• Electroporation-based delivery system for enhanced and efficient plasmid uptake to allow optimal antigen production
• Combination therapy shows robust functional antigen specific CD4+ and CD8+ killer T cells

3:15 pm Afternoon Break & Speed Networking

3:45 pm New class of Antigen-specific Cancer Active Immunotherapies based on an off-the-shelf Antigen Presenting Cell line


• PDC*line is a new potent and scalable therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells
• PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors
• The technology can be applied for any cancer

4:15 pm VB10.NEO: Development of a Personalized DNA-based Vaccine to Treat a Range of Cancers


• Industry collaboration to generate individualized cancer treatments intended for use as a therapeutic vaccination in patient with locally advanced or metastatic tumors
• Clinical data to show a clear link between selection of high-quality neoepitopes and generation of strong neoepitope-specific CD8+ T cell responses

4:45 pm Chair’s Closing Remarks

5:00 pm End of Day One